Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218365 | 0.83 | CHRM2 (0.56) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL3218353 | 0.83 | CHRM2 (0.56) | CHRNA7CHRM2CHRM1CHRM3 | |
| SCHEMBL3218557 | 0.82 | CHRNA7 (0.58) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL3222951 | 0.82 | CHRNA7 (0.58) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL3206387 | 0.82 | CHRNA7 (0.58) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL6255043 | 0.78 | MEN1 (0.60) | CHRNA7TSHRNTMT1ALDH1A1 | |
| SCHEMBL3228028 | 0.76 | SIGMAR1 (0.53) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| Hydrochloric Acid SCHEMBL8988206 | 0.76 | CHRNA7 (0.52) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL3228021 | 0.76 | SIGMAR1 (0.53) | CHRNA7CHRM2CHRM1CHRM3CHRM4 | |
| SCHEMBL7544138 | 0.75 | CHRM2 (0.54) | CHRNA7CHRM2CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171127-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6489349-B1 | TREATING AN AUTOIMMUNE DISORDER WITH AN ALKYLAMINE SUBSTITUTED PYRIDINE | TARGACEPT, INC. | 2002-12-03 | — | — | US | disclosed |
| EP-1214288-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1171127-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | Targacept, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6337351-B1 | AROMATIC OLEFIN AMINES | TARGACEPT, INC. | 2002-01-08 | — | — | US | disclosed |
| US-6310102-B1 | OXY OR HYDROXY OR NITRO SUBSTITUTED PHENYLALKYLENE AMINE DERIVATIVE USED FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER CHARACTERIZED BY AN ALTERATION IN NORMAL NEUROTRANSMITTER RELEASE | TARGACEPT, INC. | 2001-10-30 | — | — | US | disclosed |
| US-6262124-B1 | FOR ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS, FOR EXAMPLE, AS AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES; FOR THERAPY OF DYSFUNCTION OF THE CENTRAL AND AUTONOMIC NERVOUS SYSTEMS | TARGACEPT, INC., A CORPORATION OF DELAWARE | 2001-07-17 | — | — | US | disclosed |
| WO-2001017943-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| US-6166048-A | Pharmaceutical compositions for inhibition of cytokine production and secretion | TARGACEPT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1042274-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023418-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-27 | — | — | WO | disclosed |